Advertisement
BIIB vs PFE
Which Stock Would AI Choose? Biogen (BIIB) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- BIIB has shown stronger year-to-date and one-year price appreciation compared to PFE, driven by growth in its rare disease and Alzheimer’s portfolios.
- PFE offers a significantly higher dividend yield and greater revenue scale, with recent upward revisions to full-year 2026 revenue guidance following solid non-COVID product performance.
- Both companies operate in the pharmaceutical sector but differ in focus: BIIB emphasizes neuroscience and rare diseases, while PFE maintains broad exposure across oncology, vaccines, and established therapies.
- Recent regulatory progress for BIIB, including Leqembi Pen approval in Japan, has supported sentiment amid updated earnings guidance.
- PFE has benefited from operational growth in launched and acquired products and expanded cost-saving initiatives, contributing to relative stability in a volatile sector.
- Market positioning reflects trade-offs between BIIB’s higher growth volatility and PFE’s income-generating profile and larger market capitalization.
Introduction
Biogen (BIIB) and Pfizer (PFE) represent two distinct profiles within the biopharmaceutical industry, making them relevant for investors and traders assessing relative performance in healthcare equities. BIIB focuses on specialized areas such as multiple sclerosis, Alzheimer’s disease, and rare conditions, while PFE maintains a diversified portfolio spanning oncology, vaccines, and established medicines. This comparison appeals to market participants evaluating growth-oriented biotechnology exposure against large-cap pharmaceutical stability, dividend income, and sector resilience amid evolving regulatory and pipeline developments. Traders monitoring momentum shifts and investors seeking balanced healthcare allocations may find the analysis useful for understanding contrasting risk-return characteristics in the current environment.
Biogen Overview and Recent Performance
Biogen Inc. develops therapies primarily in neuroscience and rare diseases. In recent market activity, shares have traded near the upper end of their 52-week range, reflecting investor response to portfolio shifts toward newer products. Growth from the rare disease segment and Leqembi (an Alzheimer’s treatment developed with Eisai) has offset declines in legacy multiple sclerosis franchises. Recent weeks included regulatory approval of the Leqembi Pen subcutaneous formulation in Japan, expanding treatment options. The company updated 2026 guidance to a non-GAAP diluted EPS range of $15.25 to $16.25 and anticipated mid-single-digit revenue decline versus 2025, following earlier quarterly beats and acquisition-related adjustments from the Apellis Pharmaceuticals deal completed earlier in the year. Sentiment has been influenced by pipeline progress in areas such as lupus and kidney disease, alongside overall sector dynamics.
Pfizer Overview and Recent Performance
Pfizer Inc. is a global biopharmaceutical company with a broad portfolio including oncology, vaccines, and anti-infectives. Recent performance has featured upward revisions to full-year 2026 revenue guidance, raised by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion following second-quarter results. Operational growth in non-COVID products reached 18% in the quarter, supported by launched and acquired medicines. Cost-reduction initiatives have expanded, targeting additional savings through 2029. In recent weeks, the stock has shown relative resilience with a meaningful year-to-date advance, aided by pipeline updates such as positive Phase 3 data in colorectal cancer and vitiligo programs. Broader sentiment reflects steady execution on productivity measures and a high dividend yield, providing income support amid fluctuating sector conditions.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots suited to prevailing market conditions from hundreds of available options that cover thousands of tickers. These bots employ varied trading styles, strategies, timeframes, and performance statistics tailored to specific securities and market environments. Only those demonstrating consistent results and adaptability earn placement in the trending section, offering users access to data-driven signals across equities like BIIB and PFE. Available bots feature ranges of historical win rates, drawdowns, and trade frequencies that appeal to different risk tolerances. Review the platform for current selections and backtested metrics relevant to individual objectives.
Head-to-Head Comparison
Biogen and Pfizer differ markedly in business models: BIIB concentrates on high-value, specialized therapies with greater exposure to clinical and regulatory catalysts in neuroscience and rare diseases, while PFE benefits from scale, diversified revenue streams, and established cash flows supporting substantial dividends. Recent momentum favors BIIB on price appreciation metrics, though PFE has delivered more consistent operational beats and guidance lifts in its non-COVID segments. Risk factors include BIIB’s higher volatility tied to product concentration and acquisition integration, contrasted with PFE’s exposure to patent cliffs and broader competitive pressures. Sector sentiment remains constructive for both amid innovation pipelines, yet trade-offs center on growth potential versus income stability and market capitalization size.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent price behavior, stability of guidance updates, and relative positioning within the healthcare sector, Tickeron’s AI would currently assign a modestly higher probabilistic preference to BIIB for its demonstrated momentum and catalyst-driven sentiment shifts. However, PFE presents compelling attributes in revenue scale and yield that could appeal under different market regimes emphasizing defensiveness. Outcomes remain subject to evolving fundamentals and broader conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and PFE is a StrongBuy.
BIIB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 38 of 61 cases over the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 51 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
Following a +2.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 166 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BIIB broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.830) is normal, around the industry mean (-3.218). P/E Ratio (41.106) is within average values for comparable stocks, (20.770). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
PFE in +1.27% Uptrend, advancing for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 38 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 18 of 43 cases over the following month. The odds of a continued upward trend are 42%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 14 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 33 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.970) is normal, around the industry mean (-3.218). P/E Ratio (38.234) is within average values for comparable stocks, (20.770). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.058) settles around the average of (0.042) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
BIIB | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 84 | 83 | |
PRICE GROWTH RATING 1..100 | 18 | 33 | |
P/E GROWTH RATING 1..100 | 3 | 3 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (78) in the Biotechnology industry is in the same range as PFE (92) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PFE (100) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
PFE's SMR Rating (83) in the Pharmaceuticals Major industry is in the same range as BIIB (84) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (18) in the Biotechnology industry is in the same range as PFE (33) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
BIIB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as PFE (3) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
| BIIB | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 52% |
| Stochastic ODDS (%) | 1 day ago 67% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 60% | 1 day ago 44% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 42% |
| TrendWeek ODDS (%) | 1 day ago 61% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 49% |
| Advances ODDS (%) | 5 days ago 59% | 4 days ago 54% |
| Declines ODDS (%) | 12 days ago 68% | 15 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 52% |
| Aroon ODDS (%) | 1 day ago 62% | 1 day ago 61% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- BIIB’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 3 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +1.77% price change this week, while PFE (@Pharmaceuticals: Major) price change was +3.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -6.94%, and the average quarterly price growth was +1.60%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 28, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.47% | ||
| BMY - PFE | 56% Loosely correlated | -1.54% | ||
| AMGN - PFE | 52% Loosely correlated | -1.75% | ||
| BIIB - PFE | 48% Loosely correlated | +0.36% | ||
| NVS - PFE | 48% Loosely correlated | -0.28% | ||
| SNY - PFE | 47% Loosely correlated | -2.56% | ||
More | ||||